Exane Derivatives’s Regeneron Pharmaceuticals REGN Stock Holding History

Exane Derivatives’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.18K	Sell	2 -241	-99%	-$157K	﹤0.01%	492
2022 Q1	$170K	Sell	243 -275	-53%	-$174K	0.05%	377
2021 Q4	$327K	Buy	518 +248	+92%	+$152K	0.08%	250
2021 Q3	$163K	Sell	270 -198	-42%	-$123K	0.04%	439
2021 Q2	$270K	Buy	468 +93	+25%	+$47.1K	0.06%	318
2021 Q1	$177K	Buy	375 +27	+8%	+$13.1K	0.05%	319
2020 Q4	$168K	Buy	348 +155	+80%	+$83.7K	0.05%	334
2020 Q3	$108K	Buy	193 +192	+19,200%	+$116K	0.03%	292
2020 Q2	$624	Sell	1 -1,217	-100%	-$691K	﹤0.01%	592
2020 Q1	$595K	Sell	1,218 -479	-28%	-$198K	0.17%	109
2019 Q4	$663K	Buy	+1,697	New	+$571K	0.12%	133
2017 Q1	–	Sell	-4	Closed	-$1.47K	–	655
2016 Q4	$1.47K	Sell	4 -14	-78%	-$5.32K	﹤0.01%	458
2016 Q3	$7.24K	Sell	18 -47	-72%	-$18.9K	﹤0.01%	425
2016 Q2	$22.7K	Buy	65 +48	+282%	+$18.5K	﹤0.01%	321
2016 Q1	$6.13K	Hold	17	–	–	﹤0.01%	439
2015 Q4	$9.23K	Hold	17	–	–	﹤0.01%	333
2015 Q3	$7.91K	Sell	17 -98	-85%	-$52.6K	﹤0.01%	362
2015 Q2	$58.7K	Hold	115	–	–	0.01%	276
2015 Q1	$51.9K	Buy	115 +3	+3%	+$1.27K	0.01%	311
2014 Q4	$45.9K	Buy	+112	New	+$44K	0.01%	328

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Exane Derivatives's REGN Position: Q2 2022 in Review

Exane Derivatives reduced its Regeneron Pharmaceuticals (REGN) stake by 99% in Q2 2022, selling an estimated $157K and leaving 2 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Exane Derivatives first reported a position in REGN in Q4 2014 and has held it in 20 quarters since. The position peaked at $663K in Q4 2019. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Exane Derivatives held 2 shares of Regeneron Pharmaceuticals worth $1.18K as of Q2 2022.
Exane Derivatives sold 241 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $157K.
Regeneron Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #492 holding.
Exane Derivatives first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Exane Derivatives's Regeneron Pharmaceuticals position peaked at $663K in Q4 2019.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.